Apollo HealthCo targets Q1FY27 cash breakeven as Keimed merger reshapes pharmacy retail arm
Apollo Hospitals' omnichannel pharmacy and digital health unit eyes cash breakeven by Q1FY27 on FY26 revenue of ₹25,229 crore (+16% YoY). Restructuring will demerge it into Apollo Healthtech and absorb Keimed's pharma distribution, with a shareholder vote slated for June 2026.
Apollo HealthCo, Apollo Hospitals' omnichannel pharmacy and digital health arm, targets cash breakeven in Q1FY27 amid restructuring that will demerge it into Apollo Healthtech and merge Keimed pharma distribution. Shareholder vote set for June 2026.
Why this matters
Apollo HealthCo's restructuring marks a pivotal step in scaling its omnichannel pharmacy and digital health business, integrating Keimed's distribution to accelerate the path to profitability.
Retail-company signals steady at 849 over the last 90 days.